Serious adverse events (SAE) and suspected unexpected serious adverse reactions (SUSAR) in early stage patients with CLL treated with ibrutinib or placebo: safety results of the ongoing randomized CLL12 phase III-trial
作者
Petra Langerbeins,Jasmin Bahlo,Christina Rhein,Paula Cramer,Anna‐Maria Fink,Natali Pflug,Julia von Tresckow,Stephan Stilgenbauer,Karl‐Anton Kreuzer,Michael Josef Eckart,Ursula Vehling‐Kaiser,Rudolf Schlag,Christina Balser,Lothar Mueller,Marcel Reiser,Clemens‐Martin Wendtner,Kirsten Fischer,Barbara F. Eichhorst,Michael J. Hallek
出处
期刊:Universität zu Köln - Kölner Universitäts PublikationsServer日期:2017-01-01